Selected A-share Announcements | Semiconductor Manufacturing International Corporation (688981.SH) Third Quarter Report Released! Net profit exceeds 1.5 billion yuan in Q3.

Focus today 1. Semiconductor Manufacturing International Corporation: Net profit in the first three quarters increased by 41.1% year-on-year, mainly due to the increase in wafer sales volume and changes in product mix. Semiconductor Manufacturing International Corporation released the third quarter report for 2025, with revenue in the third quarter reaching 17.162 billion yuan, a year-on-year increase of 9.9%; net profit was 1.51 billion yuan, a year-on-year increase of 43.1%. Revenue for the first three quarters was 49.51 billion yuan, an increase of 18.2% year-on-year; net profit was 3.81 billion yuan, an increase of 41.1% year-on-year. The performance growth was mainly attributed to the year-on-year increase in wafer sales volume and changes in product mix. 2. Cowealth Medical China: May apply for a trading suspension review if the stock price continues to rise abnormally Cowealth Medical China announced that the cumulative increase in the company's stock price has deviated significantly from the fundamentals, and investors participating in trading may face significant risks. If the company's stock price continues to rise abnormally, the company may apply for a trading suspension review. From October 28, 2025, to November 13, 2025, the company's stock price closed at the daily limit price for twelve out of thirteen trading days, with a cumulative increase of 230.84%. As of the close on November 13, the company's stock price was 22.10 yuan per share, at a historical high. The continuous rise in the stock price poses risks of market sentiment overheating and irrational speculation, which are significantly higher than the industry and Shanghai Composite Index increases during the same period, and there are risks of rapid decline at any time. 3. Jiangxi Guotai Group: Acquires 100% equity of Beikuang Bao'an with 110 million yuan Jiangxi Guotai Group announced that it acquired 100% equity of Beijing Mining and Metallurgy Explosive Anchor Technology Engineering Co., Ltd. (referred to as "Beikuang Bao'an") through public delisting for a transaction price of 110 million yuan. 4. HPGC Renmintongtai Pharmaceutical Corporation: The company's stock price is at risk of rapid decline at any time HPGC Renmintongtai Pharmaceutical Corporation issued a notice on the abnormal fluctuations in stock trading and risk warning, stating that from November 10 to November 13, the company's stock closed at the daily limit for four consecutive trading days, with a cumulative increase of 46.43%, while the Shanghai Composite Index had a cumulative increase of 0.8% during the same period, and the pharmaceutical business (Shenwan) had a cumulative increase of 4.53%. The company's main business has not undergone significant changes, and the short-term continuous rise in the stock price poses risks of market sentiment overheating and irrational speculation, with the risk of rapid decline at any time. 5. Jiangsu HSC New Energy Materials: Stock price significantly fluctuates, with a 62% increase in revenue in the first three quarters but still incurring losses Jiangsu HSC New Energy Materials announced that the company's stock price deviated significantly from the fundamentals, having closed at the daily limit for thirty consecutive trading days from September 25, 2025, to November 13, 2025, with a cumulative deviation value of 200%. Through self-inspection, the company, controlling shareholders, and actual controllers have not concealed any material information, and the production and operation are normal. In the first three quarters of 2025, the company's revenue was 538.5553 million yuan, a year-on-year increase of 62.29%, with a net loss of 102.9745 million yuan. Due to the uncertainty in the downstream lithium battery industry, the company still faces risks of performance decline or losses, and investors are reminded to pay attention to the risks. 6. Haisco Pharmaceutical Group: Approved for clinical trials of a new indication for the innovative drug HSK39297 tablet Haisco Pharmaceutical Group announced that it recently received the "Drug Clinical Trial Approval Notice" for the HSK39297 tablet issued by the National Medical Products Administration, with the indication being age-related macular degeneration. The HSK39297 tablet is a new drug independently developed by the company with independent intellectual property rights for the treatment of age-related macular degeneration. Preclinical research results show that the drug has a clear target, definite efficacy, good safety, and is a highly promising small molecule drug with high benefit/risk ratio for clinical application. It has broad prospects for clinical application and is expected to become an effective treatment for AMD, addressing the current lack of clinical medication. More on increasing and decreasing holdings and signing large transactions are also included in the text.